Bluejay Diagnostics Files 8-K Report
Ticker: BJDX · Form: 8-K · Filed: 2025-11-10T00:00:00.000Z
Sentiment: neutral
Topics: 8-K, financial-reporting, SEC-filing
TL;DR
Bluejay Diagnostics filed an 8-K, likely with financial updates. Keep an eye out.
AI Summary
On November 10, 2025, Bluejay Diagnostics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates that Bluejay Diagnostics, Inc. is providing updates to the SEC regarding its financial statements and exhibits, which could contain material information for investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting financial statements and exhibits, with no immediate indication of negative news or significant events.
Key Players & Entities
- Bluejay Diagnostics, Inc. (company) — Registrant
- November 10, 2025 (date) — Date of earliest event reported
- 001-41031 (company) — SEC File Number
- 473552922 (company) — EIN
- 360 Massachusetts Avenue, Suite 203 (location) — Principal executive offices address
- Acton, MA 01720 (location) — Principal executive offices city, state, zip
- (844) 327-7078 (phone_number) — Registrant's telephone number
FAQ
What specific financial statements or exhibits are being filed with this 8-K?
The provided excerpt states that the filing includes 'Financial Statements and Exhibits' but does not detail the specific content of these documents.
What is the primary purpose of this 8-K filing for Bluejay Diagnostics, Inc.?
The filing is a 'Current Report' pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering 'Regulation FD Disclosure' and 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported is dated November 10, 2025.
Where is Bluejay Diagnostics, Inc. headquartered?
Bluejay Diagnostics, Inc.'s principal executive offices are located at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720.
What is the SEC file number for Bluejay Diagnostics, Inc.?
The SEC file number for Bluejay Diagnostics, Inc. is 001-41031.
Filing Stats: 484 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-11-10 16:00:46
Filing Documents
- ea0264778-8k_bluejay.htm (8-K) — 25KB
- ea026477801ex99-1_bluejay.htm (EX-99.1) — 15KB
- image_001.jpg (GRAPHIC) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- 0001213900-25-108192.txt ( ) — 251KB
- bjdx-20251110.xsd (EX-101.SCH) — 3KB
- bjdx-20251110_lab.xml (EX-101.LAB) — 33KB
- bjdx-20251110_pre.xml (EX-101.PRE) — 22KB
- ea0264778-8k_bluejay_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 10, 2025, following the prior filing on November 7, 2025 of its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025, Bluejay Diagnostics, Inc. issued a press release providing a 2025 third quarter financial and corporate update. A copy of that press release is furnished with this report as Exhibit 99.1. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended ("Securities Act"), unless specifically identified therein as being incorporated by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press release, dated November 10, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Bluejay Diagnostics, Inc. By: /s/ Neil Dey Neil Dey President and Chief Executive Officer Date: November 10, 2025 2